Further to the announcement made on September 14, Israel's Fuhrer family-owned AIT and the independent directors have reached agreement on the terms of a recommended cash acquisition to be made for UK-based generic pharmaceutical and consumer health care company Goldshield, in deal valuing you latter at round £162.1 million ($263.6 million). It is intended that the deal will be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act.
The price of 440 pence in cash for each Scheme Share represents: a premium of approximately 36% to the 323.5 pence per Goldshield share at June 23, the day before the announcement by Goldshield that it had received approaches concerning a possible offer; a 35.9% premium for the three-month period ending that date and 53% more than that prior to the original announcement. .
AIT is a newly incorporated company, formed for the purpose of implementing the acquisition.AIT is ultimately owned by the Fuhrer Family, which has significant experience in the pharmaceutical industry, owning and controlling the Neopharm group of companies, one of Israel's leading businesses dedicated to marketing premium ethical pharmaceuticals and branded consumer health care products. It is expected that the former chief executive of
Goldshield, Ajit Patel, will also invest in AIT.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze